Verdict94/ 100
Grade A · #1CoreAge Rx
The most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Visit CoreAge RxHead-to-head verdict
CoreAge Rx vs Remi Meds
Two GLP-1 providers, compared side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
Published by The GLP-1 Verdict
Pricing sources checked: CoreAge Rx: August 2026 · Remi Meds: Check date not recorded
vs
Verdict61/ 100
Grade C · #364Remi Meds
Remi Meds is a DTC compounded-GLP-1 telehealth platform offering per-dose-tier compounded semaglutide and tirzepatide-with-B12, plus NAD+, Sermorelin, and Glutathione add-ons.
Visit Remi MedsThe verdict
Winner: CoreAge Rx
CoreAge Rx takes it with a higher Verdict Score — 94/100 to 61/100 (grade A vs C). Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch. Remi Meds still earns its place — shoppers who want per-dose-tier compounded GLP-1 with named Strive Pharmacy partner.
The score compares published program terms and features; it does not measure clinical outcomes or predict which treatment will suit you.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
92Real-world results60
92
Real-world results60
97Price honesty64
97
Price honesty64
96Prescriber access49
96
Prescriber access49
88Formulary choice82
88
Formulary choice82
95Cancellation fairness56
95
Cancellation fairness56
93Member support54
93
Member support54
Price, coverage & features
| Metric | CoreAge Rx | Remi Meds |
|---|---|---|
| Verdict Score | 94/100 | 61/100 |
| Grade | A | C |
| Semaglutide | $99/mo | From $249/mo (0.25 mg dose, compounded) |
| Tirzepatide | $149/mo | From $349/mo (2.25 mg dose, compounded) |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | No | No |
CoreAge Rx
What we like
- Flat, all-in monthly price with no intro-rate step-ups after month one
- Both compounded semaglutide and tirzepatide on one account
- Available in all 50 states
- Straightforward, low-friction cancellation
The caveats
- Not the cheapest — flat-price challengers like Trimi Health and Alan Meds undercut its sticker price
- No FDA-approved brand-name option (compounded only)
- Does not yet publicly name its 503A/B pharmacy partner
Remi Meds
What we like
- Names its compounding pharmacy (Strive Pharmacy, Gilbert AZ) — stronger transparency than peers
- LegitScript verification badge on the homepage
- Publishes 503A FDCA compliance language on the tirzepatide page
- Per-dose-tier pricing fully shown — no 'as low as' floor-only obfuscation
- Operating corporate entity disclosed (T-C Health Co)
The caveats
- No named medical director, founder, or physician on any public page
- States served not listed — 'nationwide' claim with no per-state detail
- Clinical care runs through Beluga Health, a network a 2026 StatNews analysis tied to many FDA-warned GLP-1 companies (Remi Meds itself not FDA-warned)
- Year founded and corporate history are opaque
- Two phone numbers and a secondary 'Rekindle RX' email hint at shared infrastructure
Our pick — visit
Anyone who wants transparent flat pricing and nationwide access without a teaser-rate bait-and-switch.
Visit CoreAge Rx Read the full CoreAge Rx review →Also worth a look
Shoppers who want per-dose-tier compounded GLP-1 with named Strive Pharmacy partner.
Visit Remi Meds Read the full Remi Meds review →Keep comparing
Neither of these has to be the answer: the rivals we rank against CoreAge Rx cover the 7 programs closest to it, and the same shortlist for Remi Meds does the reverse.
More on CoreAge Rx
More on Remi Meds
Or browse the full comparison hub, every head-to-head A to Z and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.